ALX Oncology (ALXO) analyst forecast and price target
Analyst forecast
Consensus of 7 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Wells Fargo | Initiated Coverage | Overweight | $5.00 | Mar 19, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $4.00 | Mar 10, 2026 |
| Piper Sandler | Maintained | Overweight | $4.00 from $3.00 | Feb 5, 2026 |
| UBS | Maintained | Buy | $1.00 from $1.20 | May 21, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $2.00 from $5.00 | May 9, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $5.00 | Mar 7, 2025 |
| Stifel | Maintained | Hold | $1.50 from $3.00 | Mar 7, 2025 |
| Jefferies | Upgraded | Hold → Buy | $3.00 from $2.00 | Mar 6, 2025 |
| Piper Sandler | Maintained | Overweight | $9.00 from $8.00 | Mar 6, 2025 |
| UBS | Maintained | Buy | $2.20 from $4.00 | Jan 27, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $5.00 from $25.00 | Jan 24, 2025 |
| Cantor Fitzgerald | Maintained | Overweight | — | Jan 24, 2025 |
| Jefferies | Downgraded | Buy → Hold | $2.00 from $12.00 | Dec 19, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $25.00 | Dec 18, 2024 |
| Cantor Fitzgerald | Maintained | Overweight | — | Dec 18, 2024 |
| Cantor Fitzgerald | Maintained | Overweight | — | Nov 12, 2024 |
| UBS | Maintained | Buy | $4.00 from $25.00 | Aug 16, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $25.00 | Aug 13, 2024 |
| Cantor Fitzgerald | Maintained | Overweight | — | Aug 12, 2024 |
| Stifel | Maintained | Hold | $3.00 from $5.00 | Aug 9, 2024 |
Frequently asked questions
Is ALXO a buy, sell, or hold?
Analysts covering ALX Oncology currently average a Buy rating: 6 buy, 1 hold and 0 sell, from 7 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on ALXO?
On Mar 19, 2026, Wells Fargo initiated coverage of ALX Oncology at Overweight with a price target of $5.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.